ICU Medical (NASDAQ:ICUI) Given New $200.00 Price Target at Piper Sandler

Key Points

• Piper Sandler raised its price target on ICU Medical to $200 from $195 and maintained an “overweight” rating, implying about 19.3% upside from the prior close. Analysts’ consensus rating is “Moderate Buy,” with an average target of $193.80.
• ICU Medical beat third-quarter estimates, reporting EPS of $2.44 versus $2.14 expected and revenue of $556.22 million versus $552.03 million expected. Revenue rose 4.4% year over year.
• Despite the earnings beat, the stock was reported down 2.9%; the article also notes that insiders sold 21,830 shares worth about $3.9 million over the past three months.

ICU Medical (NASDAQ:ICUI - Get Free Report) had its price objective hoisted by analysts at Piper Sandler from $195.00 to $200.00 in a research report issued on Friday, Benzinga reports. The brokerage presently has an "overweight" rating on the medical instruments supplier's stock. Piper Sandler's target price points to a potential upside of 19.30% from the company's previous close.

Other research analysts have also issued reports about the company. Weiss Ratings upgraded ICU Medical from a "hold (c-)" rating to a "hold (c)" rating in a report on Thursday, October 8th. Needham & Company LLC raised their target price on shares of ICU Medical from $165.00 to $187.00 and gave the company a "buy" rating in a research report on Friday, August 7th. Wall Street Zen raised ICU Medical from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 8th. BTIG Research boosted their price objective on shares of ICU Medical from $170.00 to $200.00 and gave the stock a "buy" rating in a research note on Friday, August 7th. Finally, KeyCorp increased their price target on ICU Medical from $164.00 to $182.00 and gave the company an "overweight" rating in a research note on Tuesday, July 21st. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $193.80.

ICU Medical Trading Down 2.9%

Shares of NASDAQ ICUI opened at $167.65 on Friday. The company's 50 day simple moving average is $162.97 and its 200 day simple moving average is $149.18. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.43 and a quick ratio of 1.21. The firm has a market capitalization of $4.19 billion, a P/E ratio of 142.08, a P/E/G ratio of 2.17 and a beta of 0.88. ICU Medical has a fifty-two week low of $113.37 and a fifty-two week high of $192.85.

ICU Medical (NASDAQ:ICUI - Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The medical instruments supplier reported $2.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.14 by $0.30. The business had revenue of $556.22 million for the quarter, compared to analyst estimates of $552.03 million. ICU Medical had a return on equity of 7.91% and a net margin of 1.39%. The firm's revenue was up 4.4% on a year-over-year basis. During the same period last year, the company earned $2.03 EPS. On average, analysts predict that ICU Medical will post 7.22 EPS for the current year.

Insider Buying and Selling at ICU Medical

In other news, insider Ben Sousa sold 2,250 shares of ICU Medical stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $178.32, for a total value of $401,220.00. Following the transaction, the insider owned 3,076 shares in the company, valued at approximately $548,512.32. This trade represents a 42.25% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Virginia Sanzone sold 4,856 shares of ICU Medical stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $168.69, for a total value of $819,158.64. Following the completion of the transaction, the vice president owned 14,604 shares in the company, valued at approximately $2,463,548.76. This represents a 24.95% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 21,830 shares of company stock valued at $3,905,003 over the last three months. 2.10% of the stock is owned by insiders.

Institutional Investors Weigh In On ICU Medical

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Squarepoint Ops LLC acquired a new position in shares of ICU Medical in the 2nd quarter valued at about $3,744,000. Bank of America Corp DE bought a new position in shares of ICU Medical in the 2nd quarter worth $54,059,000. Legal & General Group Plc bought a new position in shares of ICU Medical in the second quarter valued at $8,444,000. Reinhart Partners LLC. acquired a new position in ICU Medical during the 2nd quarter valued at about $46,148,000. Finally, California State Teachers Retirement System boosted its position in shares of ICU Medical by 25.2% during the first quarter. California State Teachers Retirement System now owns 27,512 shares of the medical instruments supplier's stock valued at $3,553,000 after buying an additional 5,536 shares during the last quarter. Institutional investors own 96.10% of the company's stock.

ICU Medical News Summary

Here are the key news stories impacting ICU Medical this week:

• Positive Sentiment: ICU Medical reported third-quarter earnings of $2.44 per share, above the $2.14 consensus estimate and up from $2.03 a year earlier. Revenue was $556.22 million, also ahead of expectations, and increased 4.4% year over year. ICU Medical Beats Q3 Earnings and Revenue Estimates
• Positive Sentiment: The company reaffirmed fiscal 2026 guidance and said it expects results toward the high end of its previously provided range, signaling confidence in its outlook. ICU Medical Announces Q3 Results and Reaffirms Guidance
• Neutral Sentiment: Despite the earnings beat and reaffirmed guidance, the stock is lower. The articles provided do not point to a clear company-specific reason for the move. ICU Medical Q3 Adjusted Earnings, Revenue Rise

About ICU Medical

ICU Medical, Inc develops, manufactures and sells medical devices and systems used in infusion therapy, critical care and oncology. Its products are designed to support the delivery of fluids, medications and nutrition while helping healthcare providers improve safety and efficiency in clinical settings.

The company's portfolio includes infusion pumps, dedicated and non-dedicated administration sets, needle-free connectors, intravenous solutions and other infusion consumables. ICU Medical also offers products for critical care monitoring and vascular access, as well as closed-system transfer devices and related technologies used in the preparation and administration of hazardous drugs.

Founded in 1984, ICU Medical has expanded through internal development and acquisitions, including the acquisition of Hospira's infusion systems business in 2017 and Smiths Medical in 2022.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.